Start a Medical Device Reimbursement and Market Access Consultancy

1. 1

   Understand that clearance is not payment

   The single insight this business sells is that FDA clearance and getting paid are two separate battles. Clearance means a device may legally be sold; reimbursement determines whether providers can bill for using it and get paid, which decides whether they will actually buy and adopt it. A brilliant, cleared device with no coverage pathway can fail commercially, while a modest device with a clean reimbursement story thrives. Your job is the second battle, and framing it clearly to founders who assumed payment follows clearance is how you win their attention.

2. 2

   Master the three levers: coding, coverage, and payment

   Reimbursement strategy turns on three mechanisms, and clients need all three. Coding is whether an appropriate billing code (CPT and related) exists for the procedure or device use, or whether one must be pursued. Coverage is whether Medicare and private payers decide the device is medically necessary and will pay for it (national and local coverage determinations, private-payer policies). Payment is the actual dollar amount attached. Mapping a device's path through all three, and identifying where the gaps and the work are, is the core deliverable, and it is specialized knowledge most device teams simply do not have in house.

3. 3

   Add the health-economics evidence payers demand

   Payers increasingly require proof that a device improves outcomes or lowers total cost before they will cover it, which is the domain of health economics and outcomes research (HEOR). Even if you do not personally build every economic model, understanding what evidence payers need, when to generate it, and how to package the value story is central to the offer. The strongest consultants help a maker design the evidence strategy early, before launch, so the reimbursement case is ready when the device is, rather than scrambling after a coverage denial.

4. 4

   Package strategy, submissions, and ongoing advisory

   Concrete deliverables sell: a reimbursement landscape assessment for a device in development, a coding and coverage strategy, support pursuing new or revised codes, payer dossier and value-story development, and ongoing market-access advisory as coverage policies evolve. Early-stage engagements (assessing a device's reimbursement viability before heavy investment) are especially valuable, because you can save a client from building something no one will pay for, or steer the design toward a payable pathway.

5. 5

   Set up credibly and win the post-clearance makers

   LLC, professional liability insurance, engagement letters, and a portfolio built on genuine reimbursement and market-access experience, because this is deep specialist knowledge clients can quickly test. Your buyers are device makers who have cleared or are approaching clearance and now face the payment question, plus investors doing commercial diligence on device companies. Reach them through medtech commercial networks, FDA regulatory consultants (a natural referral partner, since their clients hit reimbursement next), and content that explains coverage realities plainly.

6. 6

   Grow into retainers and a broader market-access practice

   Reimbursement is not solved once; codes change, coverage policies shift, and new payers must be won, so initial strategy work converts into ongoing advisory retainers. Expand into adjacent market-access services (payer relations, value-based contracting support, international reimbursement for makers going abroad), and as demand grows, bring in HEOR and policy specialists. The practice compounds because every device maker who wants to succeed commercially, not just clear the FDA, is a potential client.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Reimbursement specialists, health economists, and commercial medtech professionals

Not for: Not for anyone without genuine reimbursement and market-access expertise, because this scarce knowledge cannot be faked and clients test it fast. Not for people who will promise coverage outcomes payers alone control. And not for those who want to sell vague advisory, since device teams need concrete, scoped deliverables on coding, coverage, and evidence.